N/A N=10 Effects of Exenatide on Overweight Adolescents With Prader-Willi Syndrome
Prader-Willi Syndrome
Primary: Change in Weight — -.5 kg — p=.07
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=38 Treatment of Hyperphagia Behavioral Symptoms in Children and Adults Diagnosed With Prader-Willi Syndrome
Hyperphagia in Prader-Willi Syndrome
Primary: Change From Baseline in Hyperphagia in Prader-Willi Syndrome (PWS) Questionnaires- Responsiveness (HPWSQ-R) Total Score at End-of-treatment (Day 15) — -15.6; -8.9 score…
Phase 2 N=12 Understanding the Role of Gut Microbiota in Hyperphagia in Prader-Willi Syndrome
Prader-Willi Syndrome · Obesity
Primary: Microbiome Analysis: Alpha Diversity — 4.89 Shannon index
Phase 2 N=32 Intranasal Oxytocin vs. Placebo for the Treatment of Hyperphagia in Prader-Willi Syndrome
Prader-Willi Syndrome · Hyperphagia
Primary: Change in Efficacy of Peptide Intranasal Oxytocin (IN-OXT) — -6.08; -6.64 score on a scale
Phase 2 N=23 Oxytocin vs. Placebo for the Treatment Hyperphagia in Children and Adolescents With Prader-Willi Syndrome
Prader-Willi Syndrome · Hyperphagia
Primary: Hyperphagia Questionnaire (HQ)- Total Score — 27.91; 30.58; 27.4; 23.33 score on a scale — p=0.059
Phase 2 N=18 Evaluation of Tolerance, Suckling and Food Intake After Repeated Nasals Administrations of Oxytocin in PWS Infants
Prader Willi Syndrome
Primary: Occurence of Adverse Event — 10; 9; 6 number of adverse events
Phase 3 N=11 Growth Hormone Use in Adults With Prader-Willi Syndrome
Prader-Willi Syndrome
Primary: Body Composition — 51.2; 48.5; 52.1 percentage of body fat — p=<0.05
N/A N=39 Early-onset Obesity and Cognitive Impairment in Children With Pseudohypoparathyroidism
Pseudohypoparathyroidism · Albright Hereditary Osteodystrophy
Primary: Intelligence Quotient — 85.9; 104.3; 103.2 units on a scale
Phase 3 N=126 A Study of Diazoxide Choline in Patients With Prader-Willi Syndrome
Prader-Willi Syndrome
Primary: Hyperphagia Questionnaire (HQ-CT) Change From Baseline at Visit 7 (Week 13) — -5.94; -4.27 score on a scale — p=0.1983
Phase 3 N=56 Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome
Metabolism and Nutrition Disorder · Obesity
Primary: Change in Body Mass Index (BMI) Standard Deviation Score (SDS) From Baseline to 16 Weeks — -0.18; -0.18; -0.50; -0.48 SDS score
Phase 2 N=19 A Study of GLWL-01 in Patients With Prader-Willi Syndrome
Prader-Willi Syndrome
Primary: Post-treatment Total Score on the Hyperphagia Questionnaire for Clinical Trials (HQ-CT) — 15.9; 14.7 score on a scale
Phase 2 N=15 Intranasal Oxytocin for Infants With Prader-Willi Syndrome
Prader-Willi Syndrome
Primary: Suck and Swallow Competency in Infants/Children With PWS Who Are in Nutritional Phase 1a — 8; 4; 1; 1 Participants — p=0.930
Phase 2 N=40 Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi Syndrome
Prader-Willi Syndrome
Primary: Number of Participants Who Experienced a Treatment-Emergent Adverse Event (TEAE) - Period 2 — 4; 11; 6; 11 Participants
Phase 2 N=65 A Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension
Prader-Willi Syndrome
Primary: Excessive Daytime Sleepiness — -3.5; -5.0; -3.9 score on a scale
N/A N=31 Pilot Study of Startle-response Test to Assess Transcranial Direct Current Stimulation-induced Modulation of Hyperphagia in Prader-Willi Syndrome
Hyperphagia · Prader-Willi Syndrome
Primary: Amplitude of Eyeblink Startle Responses — 0.006; 0.001; 0.008; 0.001 microvolts
Phase 3 N=130 Phase 3 Study of Intranasal Carbetocin (LV-101) in Patients With Prader-Willi Syndrome
Prader-Willi Syndrome
Primary: Hyperphagia Behavior — -3.439; -5.372; -2.237 score on a scale — p=0.3493
N/A N=30 Neuroendocrine Modulation of Metabolic Effects in Overweight Adolescents
Obesity
Primary: Peak Growth Hormone (GH) on the GH Stimulation Test — 40.1; 25.2 ng/ml — p=<0.05
Phase 2 N=6 Growth Hormone Treatment in Children With Phelan McDermid Syndrome
Phelan McDermid Syndrome
Primary: ABC - Social Withdrawal Subscale — 10.31; 4.6; 14.8; 6.2 score on a scale
N/A N=7 Role of Glucagon-Like Peptide-1 in Postprandial Hypoglycemia
Postprandial Hypoglycemia
Primary: Mean Plasma Glucose Area Under the Curve (AUC 0-3h) — 22,192.5; 25,207.1; 21,715.9 mg*min/dl
Phase 2 N=9 Co-administration of Tesofensine/Metoprolol in Subjects With Prader-Willi Syndrome (PWS)
Confirmed Genetic Diagnosis of Prader-Willi Syndrome
Primary: Percent Change From Baseline to End of Treatment in Mean Body Weight — -4.09; -0.38; 3.56; 3.00 Percent (%) change in mean body weight — p=0.1045
N/A N=180 Weight Change in PWS Over Six Months
Weight Change, Body
Primary: Percent of Change in Weight — 2.35 Percent of change in weight
Phase 1 N=96 GLP-1 Analogue Effects on Food Cues, Stress, Motivation for Highly Palatable Foods, and Weight
Obesity
Primary: Change in Craving Score — -0.7; -0.3 score — p=< 0.001
N/A N=71 Learning to Love Mealtime Together
Infant Obesity · Parenting · Feeding Behavior
Primary: Infant Weight-for-Length Z Scores — 0.43; 0.12 z-score — p=0.07
N/A N=16 The Role of Altered Nutrient Partitioning in Food Reward
Overweight and Obesity
Primary: Change in Preference- Liking — 6.5; 4.5 units on a scale
N/A N=31 Gastrointestinal Hormonal Regulation of Obesity
Obesity
Primary: Change in Body Weight From Baseline to 12 Months — 1.09; 1.55 lbs
Phase 3 N=42 Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity
Hypothalamic Obesity
Primary: Percent Change of Body Mass Index (BMI) as Calculated by the Formula: Body Weight in kg Divided by Height in Meters². — 1.7; 3.5 percent change from baseline — p=0.40
N/A N=8 The Effect of Macronutrients on Satiety and Gut Hormone Responses
Eating Behavior
Primary: The Effect of Proteins on the Secretion of Gut Hormones From Different Parts of the Gastrointestinal Tract — 1310; 1073; 1118; 1188 pg*min/mL
Phase 2 N=41 Biology and Experience of Eating in Women With Obesity
Obesity
Primary: Number of Participants Who Reported Nausea at 10 Minutes Post Treatment — 17; 18 Participants
Phase 1 N=10 Weight Management Program for Patients With First Episode Psychosis
Diet, Healthy · Psychotic Disorders
Primary: Weight — -6; -3; -5; -4 Lbs
Phase 3 N=12 Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity
Bardet-Biedl Syndrome · POMC Deficiency Obesity · PCSK1 Deficiency Obesity
Primary: Percentage of Participants With Greater Than or Equal to (≥) 0.2 Reduction of BMI Z-Score From Baseline to Week 52 — 85.7; 80.0 percentage of participants